[{"_1":2,"_136":-5,"_137":-5},"loaderData",{"_3":4,"_9":10},"root",{"_5":6,"_7":8},"locale","id","isCms",false,"routes/tags/$slug",{"_11":12,"_13":14,"_42":43,"_123":124,"_130":126,"_134":129,"_135":-5},"slug","limfoma","ads",[15],{"_6":16,"_17":18,"_19":20,"_21":22,"_23":24,"_25":26,"_27":28,"_29":30,"_28":31,"_32":33,"_34":35,"_36":37,"_38":39,"_40":41},"019cc7ba-cc99-73c7-8531-f093038fe91a","position_id","2f16d5c6-a732-4e00-b8c6-6306c0d32904","position_name","Sidebar Middle","position_code","sidebar_middle","name","Membaca 1","code","Membaca 2","type","image","link","https://indonesiawindow.com/lighterasi","banners/LNl7ZGDdnD0VTU52UMOugAjr6ns9lzdIRN89W13M.png","is_active",true,"description","","image_url","https://indonesiawindow.sgp1.cdn.digitaloceanspaces.com/banners/LNl7ZGDdnD0VTU52UMOugAjr6ns9lzdIRN89W13M.png","visitor",7,"created_at","2026-03-07","posts",[44],{"_6":45,"_46":47,"_11":48,"_49":50,"_51":52,"_53":54,"_55":56,"_57":58,"_59":60,"_61":62,"_63":64,"_65":66,"_67":68,"_69":70,"_71":47,"_72":47,"_73":74,"_28":75,"_76":35,"_77":78,"_36":79,"_80":81,"_82":83,"_120":121,"_40":122},"019e9c5d-41b8-7376-8c97-df6e9280e7a8","title","Obat antikanker Rocbrutinib tunjukkan respons objektif 63,9 persen dalam uji klinis","obat-antikanker-rocbrutinib-tunjukkan-respons-objektif-639-persen-dalam-uji-klinis","main_id","019bb73f-297b-7103-96b7-87ea173dc182","main_name","Iptek","main_slug","iptek-id","date","2026-06-06 00:00:00","author_id","019bb745-b426-73a2-9a49-5ddcb6765ea0","author_name","indowin","full_name","Indonesia Window","author_firstname","Indonesia","author_slug","indonesiawindow","content","

Rocbrutinib mampu menghambat mekanisme bertahan hidup sel kanker dan mengakibatkan kematian sel kanker dengan cara mengikatkan diri ke sel kanker dan mencegah protein target bernama BTK di dalam sel tersebut melalui dua jalan yang berbeda.

Guangzhou, China (Xinhua/Indonesia Window) – Rocbrutinib, obat antikanker tertarget baru, pada Kamis (4/6) mendapatkan izin edar dari Administrasi Produk Medis Nasional (National Medical Products Administration/NMPA) China. Obat revolusioner ini memberikan peluang perawatan baru bagi pasien limfoma yang mengalami resistansi terhadap obat-obatan lain.

Dikembangkan oleh perusahaan farmasi tahap klinis Lupeng Pharmaceutical yang berbasis di Guangzhou, Provinsi Guangdong, China selatan, obat oral ini mampu menghambat mekanisme bertahan hidup sel kanker dan mengakibatkan kematian sel kanker dengan cara mengikatkan diri ke sel kanker dan mencegah protein target bernama BTK di dalam sel tersebut melalui dua jalan yang berbeda.

Secara khusus, di satu sisi, obat ini dapat berikatan kuat dengan target normal secara tak dapat balik (irreversible); sementara di sisi lain, bahkan saat target telah mengalami beberapa kali mutasi yang berkaitan dengan resistansi, obat tersebut tetap mampu mengikatkan diri ke dan menghambat target tersebut, sehingga tetap efektif bagi pasien yang mengalami resistansi.

Izin itu diharapkan dapat memberikan opsi baru bagi pasien limfoma yang mengalami resistansi terhadap pengobatan sebelumnya dan hanya memiliki sedikit opsi pengobatan yang efektif.

Obat tersebut telah dimasukkan ke dalam daftar Breakthrough Therapy Designations (BTD) dari NMPA. Hasil dari uji klinis Fase II menunjukkan tingkat respons objektif sebesar 63,9 persen, tingkat respons lengkap sebesar 23 persen, dan durasi respons median 16,5 bulan.

Dengan kata lain, untuk setiap 100 pasien limfoma yang telah resistan terhadap obat-obatan lain dan hanya memiliki sedikit opsi pengobatan, sekitar 64 di antaranya mengalami penyusutan tumor signifikan, 23 di antaranya mengalami hilangnya tumor secara total berdasarkan hasil pencitraan, dan sekitar separuh di antaranya merasakan manfaat klinis yang bertahan lebih dari 16,5 bulan.

Pada 2025, sebanyak 76 obat-obatan inovatif telah mendapatkan izin di China, mencetak rekor baru dalam industri farmasi negara tersebut.

Laporan: Redaksi

","excerpt","Rocbrutinib mampu menghambat mekanisme bertahan hidup sel kanker dan mengakibatkan kematian sel kanker dengan cara mengikatkan diri ke sel k...","seo_kw","seo_title","seo_description","Rocbrutinib mampu menghambat mekanisme bertahan hidup sel kanker dan mengakibatkan kematian sel kanker dengan cara mengikatkan diri ke sel kanker.","articles/9c0OdVpUcYzGbzLTfBkt5mr58AyFJtE8Bh01J7NC.jpg","image_alt","image_caption","Ilustrasi. (Towfiqu barbhuiya on Unsplash)","https://indonesiawindow.sgp1.cdn.digitaloceanspaces.com/articles/9c0OdVpUcYzGbzLTfBkt5mr58AyFJtE8Bh01J7NC.jpg","status","publish","tags",[84,97,104,110,113],{"_6":85,"_86":87,"_23":88,"_11":89,"_28":-5,"_34":-5,"_40":90,"_91":90,"_92":93},"019bb744-689d-7369-b713-9094b633d701","old_id",9539,"metode pengobatan kanker","metode-pengobatan-kanker","2026-01-13T12:11:12.000000Z","updated_at","pivot",{"_94":45,"_95":85,"_40":96,"_91":96},"post_id","tag_id","2026-06-06T10:00:22.000000Z",{"_6":98,"_86":99,"_23":100,"_11":101,"_28":-5,"_34":-5,"_40":102,"_91":102,"_92":103},"019bb744-6f39-73c6-8f8d-a9f87adca1c8",10257,"obat kanker","obat-kanker","2026-01-13T12:11:14.000000Z",{"_94":45,"_95":98,"_40":96,"_91":96},{"_6":105,"_86":106,"_23":107,"_11":107,"_28":-5,"_34":-5,"_40":108,"_91":108,"_92":109},"019bb744-8f37-70d3-b4bc-b35f625f44ea",13379,"anti-kanker","2026-01-13T12:11:22.000000Z",{"_94":45,"_95":105,"_40":96,"_91":96},{"_6":111,"_86":-5,"_23":12,"_11":12,"_28":-5,"_34":-5,"_40":96,"_91":96,"_92":112},"019e9c60-61e2-7276-b21c-72b52131a3f5",{"_94":45,"_95":111,"_40":96,"_91":96},{"_6":114,"_86":115,"_23":116,"_11":117,"_28":-5,"_34":-5,"_40":118,"_91":118,"_92":119},"019bb744-92b5-72b7-94b5-8f378e5966de",13725,"industri farmasi","industri-farmasi","2026-01-13T12:11:23.000000Z",{"_94":45,"_95":114,"_40":96,"_91":96},"comments",[],"2026-06-06","pagination",{"_125":126,"_127":126,"_128":129,"_130":126,"_131":126,"_132":133},"count",1,"total","perPage",12,"currentPage","totalPages","links",{},"pageSize","error","actionData","errors"]